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OBJECTIVE — To estimate the rates of prevalence, diagnosis, and treatment of impaired
fasting glucose (IFG) and impaired glucose tolerance (IGT).
RESEARCH DESIGN AND METHODS — A representative sample of the U.S. popu-
lation (the National Health and Nutrition Examination Survey [NHANES]) from 2005–2006
including1,547nondiabeticadults(18yearsofage)withoutahistoryofmyocardialinfarction
was assessed to determine the proportion of adults who met the criteria for IFG/IGT, and the
proportion of IFG/IGT subjects who: 1) reported receiving a diagnosis from their physicians; 2)
were prescribed lifestyle modiﬁcation or an antihyperglycemic agent; and 3) were currently on
therapy. We used multivariable regression analysis to identify predictors of diagnosis and
treatment.
RESULTS — Ofthe1,547subjects,34.6%(CI30.3–38.9%)hadpre-diabetes;19.4%hadIFG
only;5.4%hadIGTonly,and9.8%hadbothIFGandIGT.Only4.8%ofthosewithpre-diabetes
reportedhavingreceivedaformaldiagnosisfromtheirphysicians.Nosubjectswithpre-diabetes
received oral antihyperglycemics, and the rates of recommendation for exercise or diet were
31.7% and 33.5%, respectively. Among the 47.7% pre-diabetic subjects who exercised, 49.4%
reported exercising for at least 30 min daily.
CONCLUSIONS — Three years after a major clinical trial demonstrated that interventions
could greatly reduce progression from IFG/IGT to type 2 diabetes, the majority of the U.S.
population with IFG/IGT was undiagnosed and untreated with interventions. Whether this is
duetophysiciansbeingunawareoftheevidence,unconvincedbytheevidence,orclinicalinertia
is unclear.
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A
n estimated 26% of the U.S popu-
lation (54 million) suffered from
impaired fasting glucose (IFG) as
of 2003 (1), and an estimated 15.8%
(32 million) had impaired glucose tol-
erance (IGT) in 1994 (2). In 2002, a
randomized clinical trial (the Diabetes
Prevention Project [DPP]) demon-
strated that lifestyle modiﬁcation and
oral antihyperglycemics, speciﬁcally
metformin, can delay or prevent pro-
gression to type 2 diabetes (3). Conse-
quently, in 2005 the American Diabetes
Association (ADA) recommended the
oralantihyperglycemic,metformin,and
lifestyle modiﬁcation for those with IFG
and/or IGT (4).
Those with IFG, IGT, or both are at
greater risk for cardiovascular disease
than those with normal glucose metab-
olism, though their glycometabolic ab-
normalities do not yet qualify for a
diagnosisoftype2diabetes(5–9).Since
type 2 diabetes is associated with even
greater cardiovascular risk than pre-
diabetes, preventing type 2 diabetes
may improve cardiovascular outcomes
regardless of the impact on other car-
diovascular risk factors. The DPP has
demonstrated that progression of IFG/
IGT to type 2 diabetes can be prevented
or delayed by lifestyle modiﬁcation and
pharmacological interventions (3).
Nostudiestodatehavequantiﬁedthe
combined prevalence of IFG and IGT and
their rates of diagnosis and treatment. In
addition, no studies have examined the
rates of adherence to these therapies. Us-
ing data obtained from a nationally repre-
sentative sample of the U.S. population
three years after publication of the DPP
(theNationalHealthandNutritionExam-
ination Survey [NHANES] IV), we as-
sessed the proportion of adults who met
the criteria for IFG/IGT, and the propor-
tion of IFG/IGT subjects who:1) reported
receiving a formal diagnosis from their
physicians; 2) reported having lifestyle
modiﬁcation or an oral hypoglycemic
agentrecommended;and3)wereactively
doing lifestyle modiﬁcation or using an
oral hypoglycemic agent.
RESEARCH DESIGN AND
METHODS
Data source
NHANESisacross-sectionalsurveyofthe
health and nutrition of the noninstitu-
tionalized, household-dwelling U.S. pop-
ulation conducted by the National Center
forHealthStatisticsandbytheCentersfor
Disease Control and Prevention (10,11).
The survey consists of two components:
the in-home interview and the mobile
exam center, which performs several lab-
oratory tests including the fasting plasma
glucose (FPG) test and the 2-hr oral glu-
cose tolerance test (OGTT). The in-home
survey collects demographic and clinical
information, including the subject’s age,
race, sex, medical history, therapy, and
lifestyle variables such as the frequency
and duration of exercise and dietary
habits.
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NHANES has collected data in 2-year co-
horts since 1999. The 2005–2006 sam-
ple from NHANES IV, the most recent
publicly available version, was used in
this study. We restricted our analyses to
the subjects in the subsample that had
morning examinations since they were
the only subjects who had valid FPG
and OGTT testing. We also excluded
from our analyses subjects aged 18
years, those with diagnosed or undiag-
nosed diabetes, and those with a history
of myocardial infarction (MI).
Study variables and deﬁnitions
The current ADA deﬁnition for IFG is
blood glucose 100–125 mg/dl after an
8-h fast (12). When the IFG category was
initially introduced by the ADA, IFG was
deﬁnedas110–125mg/dlafterfasting.In
2003, the ADA lowered the threshold of
IFG to better capture those who met the
World Health Organization’s (WHO) cri-
teria for IGT. WHO deﬁnes IGT as a glu-
cose level of 140–199 mg/dl 2 h after a
glucose load (13). We compared the esti-
mates of the prevalence of pre-diabetes
using the old and the new fasting blood
glucose criterion.
Subjects were asked if their physi-
cians have ever told them that they have
“borderline diabetes, pre-diabetes, im-
paired fasting glucose, or impaired glu-
cose tolerance.” A prior diagnosis of pre-
diabetes was considered to be a “yes” to
any of the four terms.
The ADA recommends metformin
alone as the antihyperglycemic of
choice based upon the DPP results.
However, because NHANES does not
indicate the class of antihyperglycemic
used for IFG/IGT, we could only deter-
mine whether any antihyperglycemic
medication was given. Lifestyle modiﬁ-
cation included either exercise, diet
modiﬁcation, or both. Subjects who av-
eraged at least 30 min of vigorous or
moderate activity daily for the previous
30 days were considered “compliant”
with ADA recommendations for treat-
ment of IFG/IGT (4). Vigorous activity
was deﬁned as activity that causes
“heavy sweating or large increases in
breathingorheartrate.”Moderateactiv-
ity was deﬁned as activity that causes
“moderate sweating or slight to moder-
ate increases in breathing or heart rate.”
Subjects were asked if they maintained
their activity levels over the last year
relativetothelast30days.Providerrec-
ommendation for diet modiﬁcation in-
cluded reporting either counseling to
reduce weight or counseling to reduce
fat/calorieintake,orboth.NHANESdid
not indicate the chronological order of
thephysicianrecommendationsandthe
actual change in exercise or diet, so it
was not possible to determine if lifestyle
behaviors changed in response to the
recommendations.
Statistical analyses
Theassociationsbetweensubjectdemo-
graphics and medical conditions and
thepresenceofpre-diabeteswereexam-
inedusingthe
2 statisticforcategorical
predictor variables and logit modeling
for continuous predictor variables.
Sampling weights were used to provide
estimates that are representative of the
U.S. population; all percentages pre-
sented are weighted. Most variables an-
alyzed had little missing data (4%),
but16.7%ofsubjectsweremissingdata
for either income, education, or both.
Therefore, multiple imputation was
used to more accurately account for the
high level of missing data for all analy-
ses involving these two variables (14).
Multivariable logistic regression was
used to examine independent predic-
tors of treatment and adherence to
lifestyle modiﬁcation therapies. Inde-
pendent variables in the model in-
cluded sex, race, education, insurance
status, and the percent of poverty level.
All statistical analyses were performed
using the STATA software (version
10.0; StataCorp LP, College Station,
TX).
RESULTS
Study population
The NHANES 2005–2006 cohort in-
cluded 2,425 subjects aged 18 years or
older in the morning examination (fast-
ing) sample. From this sample, 878 were
excluded from our analysis: 87 because
they had had a prior MI (since we were
interested in pre-diabetes and diabetes as
coronary artery disease risk factors); 659
because they had missing OGTT data; 16
becausetheyhaddiagnoseddiabetes;and
116becausetheyhadundiagnoseddiabe-
tes (based on FPG and/or OGTT testing).
Subjectswhowereonoralmedicationsor
receiving insulin for their diagnosed dia-
betes were excluded from OGTT testing;
hence,only16subjectswereexcludedfor
diagnosed diabetes and 116 for undiag-
nosed diabetes. These exclusions resulted
inasampleof1,547subjectsinthestudy.
By applying sample weights to make the
results representative of the nondiabetic
U.S. population without a history of MI,
we estimate that about 34.6% (CI 30.3–
38.9%) of nondiabetic U.S. adults had
pre-diabetes.Ofthepre-diabeticsubjects,
84% met IFG criteria, 44% met IGT cri-
teria, and 28% met both. Using the 1997
ADAcriteriaforIFG(110–125mg/dl)re-
sulted in 43% fewer subjects meeting the
criteria for IFG, reducing the estimate of
the prevalence of pre-diabetes in nondia-
betic U.S. adults from 34.6 to 19.8%
(Table 1).
Demographics and medical
conditions
The subjects’ demographic characteris-
ticsandmedicalconditionsarereported
in Table 2. Those with pre-diabetes had
substantiallyhighercardiovascularrisk,
with a mean Framingham 10-year risk
for cardiovascular events of 8.5% (CI
6.0–10.6%), which was almost twice
that of normoglycemic subjects (5.2%
[CI 3.9–6.4%], P  0.001) (15,16).
Only 3.4% of the entire study sample
reported a prior diagnosis of “impaired
fasting glucose, impaired glucose toler-
ance, borderline diabetes, or pre-
diabetes” (Table 2). Of those reporting a
diagnosis, 38.5% no longer met the pre-
diabetes criteria (either due to resolution
or misdiagnosis); 61.5% had unresolved
pre-diabetes. No diagnosed pre-diabetic
subjects reported receiving oral antihy-
Table 1—Prevalence of pre-diabetes in 2005–2006 of a nationally representative sample of
1,547 nondiabetic U.S. adults using older vs. newer ADA criteria
1997 ADA criteria 2003 ADA criteria
(110  FPG 125) (100  FPG 125)
Pre-diabetes 19.8 (16.3–23.3) 34.6 (30.3–38.9)
IFG only 4.5 (3.0–6.0) 19.4 (16.3–22.4)
IGT only 11.8 (9.2–14.3) 5.4 (3.5–7.3)
IFG and IGT 3.5 (2.1–4.9) 9.8 (7.5–12.0)
Pre-diabetes  having either IFG or IGT.
Diagnosis and treatment of pre-diabetes
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Multivariable analysis found that subjects
who had pre-diabetes tended to be older,
male, and Mexican American (Table 3).
Recommendations for and practice
of diabetes prevention behaviors
Ofpre-diabeticsubjects,31.7%(CI23.3–
40.2%) reported receiving counseling
for exercise, 33.4% (CI 26.4–40.5%) for
diet, and 25.9% (CI 17.9–34.5%) for
both(Table4).Ofthosewhoreportedex-
ercising, only about half reported achiev-
ingtheADAIFG/IGTguidelinesofatleast
30 min daily. Rates of recommendations
forandpracticeofdiabetespreventionbe-
haviors were similar when the 1997 ADA
criteria for IFG (FPG of 110–125 mg/dl)
were applied.
CONCLUSIONS— This study is the
ﬁrst to publish a combined estimate of
IFG/IGTandexploreitscontemporarydi-
agnosis and treatment patterns in a na-
tional sample. Using NHANES data
gathered roughly 3 years after the publi-
cation of the DPP, we found that the ma-
jority of people with IFG and/or IGT are
undiagnosed and untreated with inter-
ventions that the DPP suggests can sub-
stantially reduce progression to type 2
diabetes, reducing the risk of both
microvascular and macrovascular
complications.
Delays in the adoption of effective
new therapies have been commonly re-
ported. However, given the signiﬁcant
potential beneﬁts of metformin and life-
style modiﬁcation, the very low level of
detection and intervention are concern-
ing. In the DPP randomized trial, life-
style modiﬁcation and metformin
reducedtheincidenceoftype2diabetes
by 58 and 38%, respectively, in just 3
years (15–17).
We found similar rates of prevalence
of IFG and IGT in reports from earlier
time periods (1,2) and found a combined
prevalence of 34.6% nondiabetic U.S.
adults. Consistent with prior studies, rel-
ative to normoglycemic subjects, pre-
diabetic subjects in this cohort tended to
beolder,male,MexicanAmerican,hyper-
tensive, hyperlipidemic, and have sub-
stantially greater overall 10-year
cardiovascular risk.
Disappointingly, only 3.4% of pre-
diabetes individuals reported that their
physicians diagnosed them with pre-
diabetes. This extremely low rate could in
part be due to incomplete recollection by
subjects or because physicians did not
emphasizetheimportanceofpre-diabetes
to their patients. Another likely explana-
tion is that physicians do not adequately
screen for and diagnose pre-diabetes, re-
sulting in marked underdiagnosis of pre-
diabetes. For instance, physicians did not
recommend lifestyle modiﬁcation to pre-
diabetic subjects any more intensively
than normoglycemic subjects. In addi-
tion, not one subject reported receiving
metformin, suggesting that physicians
were either unaware of metformin’s ben-
eﬁts, were hesitant to prescribe it, or were
unaware the subject had pre-diabetes;
however, it is also possible that many
physicians are aware of the DPP ﬁndings,
but found its results unconvincing.
Three years after the DPP, however,
subjects reported that lifestyle interven-
tions were recommended to less than
one-thirdofpre-diabeticsubjects.Ofpre-
diabetic subjects, less than half reported
exercising, less than two-thirds reported
recentattemptsatweightand/ordietcon-
trol, and 44% reported both. Though it
could be argued that the recent formal
guidelines may improve upon practice at
the time of study (our NHANES cohort
Table 2—Demographic and medical information for the study population (a nationally rep-
resentative sample of 1,547 nondiabetic U.S. adults in 2005–2006)*
Demographics Normoglycemic Pre-diabetes P value
n 963 584
Age (mean) 39.6 (38.0–41.3) 49.3 (46.8–51.9) 0.001
Male (%) 43.1 (40.9–45.3) 59.0 (53.3–64.6) 0.001
Race (%)
White 72.5 (67.2–77.7) 69.1 (61.1–77.2) 0.2
Black 11.8 (7.9–15.6) 10.4 (6.4–14.4)
Hispanic 10.8 (8.6–13.0) 14.4 (9.7–19.1)
Other/multiracial 5.0 (2.4–7.5) 6.0 (2.7–9.3)
Insured (%) 79.7 (74.0–85.3) 80.5 (75.1–85.8) 0.2
Current cigarette smoking (%) 29.8 (24.5–35.2) 19.7 (14.6–24.8) 0.001
Education (%)
High school 12.3 (9.3–15.4) 19.7 (15.1–24.4) 0.001
High school graduate 24.7 (20.7–28.8) 24.4 (20.3–28.5)
Some college 62.9 (57.2–68.7) 55.9 (50.4–61.3)
Income (%)
Poverty level 9.3 (7.0–11.6) 10.1 (7.2–13.0) 0.2
100–200% of poverty level 17.4 (12.3–22.4) 20.4 (14.7–26.2)
200% poverty level 73.3 (68.1–78.6) 73.3 (68.1–76.5)
BMI (mean) 26.8 (26.3–27.4) 30.7 (29.7–31.8) 0.001
Blood pressure (mean  SD,
mmHg)
Systolic 116.8 (115.4–118.1) 125.2 (123.5–127.1) 0.001
Diastolic 67.9 (66.5–69.3) 70.0 (68.8–71.2) 0.013
Cholesterol (mean  SD,
mg/dl)
Total 194.4 (190.0–198.7) 202.6 (197.1–208.1) 0.004
HDL 57.1 (55.9–58.3) 53.1 (51.6–54.6) 0.001
Past medical history of pre-
diabetes (%) 1.7 (1.1–2.4) 4.8 (3.1–6.5) 0.003
Interventions (%)
Exercise recommended only 23.7 (19.5–30.0) 31.7 (23.3–40.2) 0.001
Diet recommended only 16.6 (12.4–20.7) 27.4 (20.3–34.5) 0.001
Mean 10-year cardiovascular
risk (mean) 5.2 (3.9–6.4) 8.3 (6.0–10.6) 0.001
Hemoglobin A1C (mean) 5.1 (5.1–5.2) 5.4 (5.4–5.5) 0.001
Fasting serum glucose (mean,
mg/dl) 91.2 (90.6–91.9) 105 (104.2–105.9) 0.001
2-h postglucose load test
(mean, mg/dl) 92.8 (90.8–94.8) 128.9 (125.5–132.4)
0.001
*Thestudypopulationisa2005–2006nationallyrepresentativesampleofnondiabeticU.S.adults.Statistical
signiﬁcance was tested using 
2 testing for differences in percentages and t testing for differences in means.
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Services Task Force and ADA guidelines
were published around this time), most
evidence suggests that passive dissemina-
tion of national guidelines is ineffective in
changing clinical practice.
While substantial evidence has dem-
onstrated the beneﬁts of early glycemic
control in reducing the incidence of type
2 diabetes, whether early glycemic con-
trol signiﬁcantly reduces cardiovascular
outcomes has been debated. However,
unlike most studies of early or intensive
antihyperglycemic medication interven-
tions, intervention with a lifestyle modiﬁ-
cation in pre-diabetes substantially
improved cardiovascular risk factors in
the DPP (such as blood pressure and lip-
ids), making it likely that such interven-
tions will improve cardiovascular
outcomes(18).Itisalsopossiblethatlow-
ering the lifetime glycemic burden by
earlyinterventioncouldreducelong-term
cardiovascular outcomes, as seen in the
17-yearfollow-upoftheDiabetesControl
andComplicationsTrial(DCCT)(19).Fi-
nally, the cardiovascular risk associated
with overt type 2 diabetes is substantially
greater than the cardiovascular risk asso-
ciated with pre-diabetes, suggesting that
delaying or preventing type 2 diabetes
should improve both cardiovascular and
microvascular outcomes regardless of the
directimpactonothercardiovascularrisk
factors (20).
The limitations of our study include
large amounts of missing data for smok-
ing,particularlywhencalculatingtheFra-
minghamriskscore.Inaddition,therates
ofphysiciandiagnosisweredependenton
subject self-report and were not veriﬁed
by chart abstraction; consequently the
rates of diagnosis and treatment of IFG/
IGT may have been underreported. Also,
only subjects reporting pre-diabetes were
asked about whether they were on oral
hypoglycemicmedications,sosomeaddi-
tionalsubjectsmayhavebeentreatedthat
were not captured in our results.
NHANES also does not report the chro-
nological order of diagnosis, recommen-
dation, and treatment. Finally, the ADA
2003 criteria for IFG resulted in a dra-
matic increase in the number of people
being diagnosed with IFG and has been
controversial; many physicians may dis-
Table3—Independentassociationswiththepresenceofpre-diabetes(a2005–2006nationally
representative sample of 1,546 nondiabetic U.S. adults)
Predictors
Unadjusted association Adjusted associations*
OR (95% CI) P OR (95% CI) P
Male 1.90 (1.54–2.34) 0.001 2.30 (1.75–3.01) 0.001
Age (per decade of life) 1.46 (1.38–1.55) 0.001 1.58 (1.45–1.72) 0.001
Race (ref  white)
Black 0.93 (0.68–1.26) 0.2 1.15 (0.86–1.54) 0.2
Mexican American 1.47 (1.00–2.17) 0.05 1.96 (1.10–3.48) 0.03
Other/multiracial 1.26 (0.70–2.27) 0.2 1.54 (0.82–2.88) 0.16
Insured 1.05 (0.76–1.46) 0.2 0.99 (0.68–1.45) 0.2
Education (ref  some college
or more)
High school graduate 1.11 (0.81–1.53) 0.2 0.92 (0.67–1.26) 0.2
High school 1.80 (1.42–2.29) 0.001 1.28 (0.96–1.71) 0.09
Income (ref  200% poverty)
Poverty level 1.15 (0.78–1.70) 0.2 1.29 (0.84–1.99) 0.2
100%–200% poverty level 1.24 (0.75–2.05) 0.2 1.12 (0.63–2.00) 0.2
*Independent associations in a multiple logistic regression model controlling for all listed variables. OR,
odds ratio; ref, reference.
Table 4—Subject-reported recommendations for and practice of diabetes prevention behaviors for 584 subjects with pre-diabetes in a
2005–2006 nationally representative sample of U.S. adults*
Interventions
Reported
diabetes
prevention
behavior
Reported receiving a
recommendation for
a diabetes
prevention behavior
Of those reporting receiving
a recommendation, %
reporting diabetes
prevention behavior
Exercise (%) 47.7 (43.2–52.2) 31.7 (23.3–40.2) 70.0 (61.7–78.4)
Vigorous exercise, of those exercising (%) 47.2 (39.9–54.5) † †
Moderate exercise, of those exercising (%) 22.5 (17.7–27.3) † †
Mean METs, of those exercising 5.2 (5.0–5.4) † †
Exercise 30 min daily, of those exercising 49.4 (43.6–55.1) † †
Change in exercise in past year, for all pre-diabetics
Increased activity 22.5 (17.7–27.3) † †
Same activity 56.2 (51.0–61.4) † †
Decreased activity 21.2 (16.5–26.0) † †
Control their diet or weight (%) 62.1 33.5 (26.4–40.5) 86.0 (79.4–92.5)
Control weight (%) 51.9 (47.1–56.6) 27.4 (20.3–34.5) 72.2 (62.6–81.9)
Reduce fat/calories (%) 53.9 (48.3–60.0) 29.0 (21.8–36.2) 83.2 (77.0–90.0)
Diet  exercise (%) 44.4 (40.7) 25.9 (17.2–34.5) 69.1 (61.0–77.3)
Oral antihyperglycemic 0 (0–10.8)‡ † †
*Data were only available on patient behavior, if recommendation for exercise was given at all. NHANES did not indicate the chronological order of the physician
recommendationsandtheactualchangeinexerciseordietsoitisnotpossibletodetermineiflifestylebehaviorschangedinresponsetorecommendations.Applying
WHO IFG criteria (FPG 110–125) showed similar results. †Rates of recommendation for these speciﬁc exercise categories were not reported in NHANES. ‡Only
available for those with diagnosed pre-diabetes.
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nosis. However, the 20% of the
population who met 1997 ADA pre-
diabetes criteria had similar results of rec-
ommendation and compliance with
lifestyle modiﬁcation measures as did
those who met the new ADA pre-diabetes
criteria.
Three years after a landmark study
demonstrated that early diagnosis of and
intervention of pre-diabetes can substan-
tially reduce progression to type 2 diabe-
tes, the majority of people with IFG
and/or IGT were undiagnosed and un-
treated. Whether this is due to physicians
being unaware of the evidence, uncon-
vinced by the evidence, or clinical inertia
is unclear. Consideration should be given
to national policies to improve upon this
situation such as public and provider ed-
ucation programs.
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